Choosing the right macrolide antibiotic - A guide to selection

被引:22
作者
Charles, L [1 ]
Segreti, J [1 ]
机构
[1] RUSH MED COLL, CHICAGO, IL 60612 USA
关键词
D O I
10.2165/00003495-199753030-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Macrolide antibiotics have proven to be valuable alternatives to penicillins and cephalosporins for the treatment of a number of infections. Currently, a number of macrolides are available. When choosing a particular macrolide, the types of organisms causing the infection, the tolerability of the drug, convenience of dosing and possible drug interactions all must be taken into account. Erythromycin, azithromycin and clarithromycin are equally effective against most gram-positive organisms. However, clarithromycin and azithromycin have much better activity against Haemophilus influenza and Moraxella catarrhalis. Thus, these 2 drugs are better choices for the treatment of community-acquired pneumonia. However, the low serum concentrations of azithromycin may be a problem in patients with bacteraemia associated with with community-acquired pneumonia. Clarithromycin appears to be effective for the treatment and prophylaxis of Mycobacterium avium complex (MAC) in patients with AIDS, while azithromycin appears to be effective for prophylaxis. Treatment of MAC with azithromycin is currently undergoing study. Although clarithromycin is the macrolide of choice for the treatment of Helicobacter pylori, azithromycin is the preferred macrolide for the treatment of Chlamydia trachomatis infections. The major factor limiting the use of azithromycin and clarithromycin has been their cost. However, these drugs may be cost effective if compliance is improved due to better tolerability and more convenient dosing regimens.
引用
收藏
页码:349 / 357
页数:9
相关论文
共 105 条
[1]   EFFICACY OF CLARITHROMYCIN FOR TREATMENT OF EXPERIMENTAL LYME-DISEASE INVIVO [J].
ALDER, J ;
MITTEN, M ;
JARVIS, K ;
GUPTA, P ;
CLEMENT, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1329-1333
[3]   Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla [J].
Alper, CM ;
Doyle, WJ ;
Seroky, JT ;
Bluestone, CD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1889-1892
[4]   COMPARISON OF THE EFFECTS OF THE NEW AZALIDE ANTIBIOTIC, AZITHROMYCIN, AND ERYTHROMYCIN ESTOLATE ON RAT-LIVER CYTOCHROME-P-450 [J].
AMACHER, DE ;
SCHOMAKER, SJ ;
RETSEMA, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1186-1190
[5]   A COMPARATIVE SAFETY AND EFFICACY STUDY OF CLARITHROMYCIN AND ERYTHROMYCIN STEARATE IN COMMUNITY-ACQUIRED PNEUMONIA [J].
ANDERSON, G ;
ESMONDE, TS ;
COLES, S ;
MACKLIN, J ;
CARNEGIE, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :117-124
[6]  
ARGUEDAS AG, 1996, 3 INT C MACR AZ STRE
[8]   CLARITHROMYCIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN MYCOBACTERIUM-AVIUM-INTRACELLULARE COMPLEX INFECTION IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME [J].
BARRADELL, LB ;
PLOSKER, GL ;
MCTAVISH, D .
DRUGS, 1993, 46 (02) :289-312
[9]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[10]   INVITRO ACTIVITY OF A-56268 (TE-031), A NEW MACROLIDE, COMPARED WITH THAT OF ERYTHROMYCIN AND CLINDAMYCIN AGAINST SELECTED GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS [J].
BENSON, CA ;
SEGRETI, J ;
BEAUDETTE, FE ;
HINES, DW ;
GOODMAN, LJ ;
KAPLAN, RL ;
TRENHOLME, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (02) :328-330